NCT05563480 2026-04-07
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
Clinical Trials
9 trialsNCT06821503 2026-03-10
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT07381075 2026-02-02
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
West China Hospital
Phase 2 Not yet recruiting
NCT05807880 2026-01-23
ALTER-HN005
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05001971 2026-01-15
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy
Hunan Cancer Hospital
Phase 2 Completed
NCT06825494 2025-12-18
Clinical Studies for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT05576480 2025-08-28
SPARC
Ruijin Hospital
Phase 2 Recruiting
NCT07075419 2025-07-20
JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure
West China Hospital
Phase 1/2 Not yet recruiting
NCT06943820 2025-06-03
AK129 Combination Therapy for Advanced Solid Tumors
Akeso
Phase 1/2 Recruiting